123M 24.6%
Total Revenue QoQ (USD) - Q2 '24

Sign up to access historical data

Sign up

Income Statement (USD)

Q2 '24 QoQ
Revenue 123M 24.6%
Gross Profit 67M 124.1%
Cost of Revenue 56M 18.4%
Operating expense 44M 25.7%
Net Income 41M 75.3%
EBITDA 64M 74.4%

Balance Sheet (USD)

Q2 '24 QoQ
Total Assets 706M 9.2%
Total Liabilities 98M 14.6%
Total Equity 609M 8.4%
Shares Outstanding 119M 0.4%

Cash Flow (USD)

Q2 '24 QoQ
Cash from operations 64M 100.9%
Cash from investing -10,000 95%
Cash from financing 1.2M 99.2%

EPS

Only available for members.

Financial Highlights for Catalyst Pharmaceuticals in Q2 '24

Catalyst Pharmaceuticals reported a revenue of 123M, which is a 24.6% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.

Gross Profit stood at 67M, marking a 124.1% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.

Cost of Revenue was 56M, a -18.4% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.

Operating Expenses for this period were 44M, showing a -25.7% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.

Net Income for the quarter was 41M, showing a 75.3% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.

The company's EBITDA for the quarter was 64M, showing a 74.4% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.

It was a positive quarter for Catalyst Pharmaceuticals with growth in revenue, gross profit, and net income.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.